JP2004533250A - 分泌された細菌エフェクタータンパク質の薬学的使用 - Google Patents

分泌された細菌エフェクタータンパク質の薬学的使用 Download PDF

Info

Publication number
JP2004533250A
JP2004533250A JP2002592975A JP2002592975A JP2004533250A JP 2004533250 A JP2004533250 A JP 2004533250A JP 2002592975 A JP2002592975 A JP 2002592975A JP 2002592975 A JP2002592975 A JP 2002592975A JP 2004533250 A JP2004533250 A JP 2004533250A
Authority
JP
Japan
Prior art keywords
cell
domain
cells
effector protein
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002592975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004533250A5 (https=
Inventor
マーク サットン，ジョン
チャールズ ショーン，クリフォード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Public Health England
Original Assignee
Health Protection Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Protection Agency filed Critical Health Protection Agency
Publication of JP2004533250A publication Critical patent/JP2004533250A/ja
Publication of JP2004533250A5 publication Critical patent/JP2004533250A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2002592975A 2001-05-24 2002-05-21 分泌された細菌エフェクタータンパク質の薬学的使用 Pending JP2004533250A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0112687.9A GB0112687D0 (en) 2001-05-24 2001-05-24 Pharmaceutical use of secreted bacterial effector proteins
PCT/GB2002/002384 WO2002096467A2 (en) 2001-05-24 2002-05-21 Pharmaceutical use for secreted bacterial effector proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009202601A Division JP2009286794A (ja) 2001-05-24 2009-09-02 分泌された細菌エフェクタータンパク質の薬学的使用

Publications (2)

Publication Number Publication Date
JP2004533250A true JP2004533250A (ja) 2004-11-04
JP2004533250A5 JP2004533250A5 (https=) 2005-12-22

Family

ID=9915236

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002592975A Pending JP2004533250A (ja) 2001-05-24 2002-05-21 分泌された細菌エフェクタータンパク質の薬学的使用
JP2009202601A Pending JP2009286794A (ja) 2001-05-24 2009-09-02 分泌された細菌エフェクタータンパク質の薬学的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009202601A Pending JP2009286794A (ja) 2001-05-24 2009-09-02 分泌された細菌エフェクタータンパク質の薬学的使用

Country Status (8)

Country Link
US (1) US20040208889A1 (https=)
EP (1) EP1390400A2 (https=)
JP (2) JP2004533250A (https=)
CN (1) CN100439394C (https=)
AU (1) AU2002256803B2 (https=)
CA (1) CA2448963A1 (https=)
GB (1) GB0112687D0 (https=)
WO (1) WO2002096467A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535514A (ja) * 2005-04-11 2008-09-04 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド キメラタンパク質、それらの製造およびそれを含有する医薬組成物
JP2014518061A (ja) * 2011-06-01 2014-07-28 シャモン ユニヴァーシティー ジフテリア毒素の無毒性突然変異体ｃｒｍ１９７又はその断片を含む融合タンパク質

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US8012491B2 (en) * 1996-08-23 2011-09-06 Syntaxin, Ltd. Recombinant toxin fragments
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
US6991789B2 (en) * 2004-06-29 2006-01-31 Allergas, Inc. Methods of modulating intracellular degradation rates of toxins
DE102004035606A1 (de) * 2004-07-22 2006-03-30 Biotecon Therapeutics Gmbh Carrier für Arzneimittel zur Gewinnung der oralen Bioverfügbarkeit
WO2006137836A2 (en) * 2004-08-17 2006-12-28 Research Development Foundation Bacterial vector systems
US20090092652A1 (en) * 2004-08-20 2009-04-09 Children's Medical Center Corporation Method for the inhibition of angiogenesis or cancer using protective antigen related molecules
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
JP5714692B2 (ja) * 2010-03-23 2015-05-07 イーエムベーアー−インスティトゥート・フューア・モレクラレ・ビオテヒノロギー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＩｍｂａ−Ｉｎｓｔｉｔｕｔ Ｆｕｅｒｍｏｌｅｋｕｌａｒｅ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅ Ｇｍｂｈ Ｉｉｉ型分泌機構の阻害剤の同定方法
WO2012054693A1 (en) * 2010-10-22 2012-04-26 Trudeau Institute Uses of yersinia yope peptide, gene, and subparts thereof as a plague vaccine component and assays for yersinia pestis-specific t cells
CN108137654A (zh) * 2015-05-15 2018-06-08 内布拉斯加大学董事会 适用于将分子递送进入选定细胞的工程改造的肉毒梭菌毒素
GB201609216D0 (en) 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
US20210054033A1 (en) * 2018-01-25 2021-02-25 The Wistar Institute Of Anatomy And Biology Methods and compositions for use of recombinant bacterial effector proteins as anti-inflammatory agents
WO2022087856A1 (zh) * 2020-10-26 2022-05-05 南京吉芮康生物科技研究院有限公司 一种减毒沙门氏菌分泌表达rbd结构域蛋白的新型冠状病毒疫苗抗原递呈系统及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2498192A2 (fr) * 1981-01-22 1982-07-23 Pasteur Institut Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications
WO1983003971A1 (en) * 1982-05-12 1983-11-24 President And Fellows Of Harvard College Hybrid proteins
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
EP0760681B1 (en) * 1994-05-31 1999-09-01 Allergan, Inc Modification of clostridial toxins for use as transport proteins
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5972899A (en) * 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
SE9702191D0 (sv) * 1997-06-09 1997-06-09 Sven Pettersson Coposition and methods for the treatment of inflammatory dideases
US5965381A (en) * 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
US6485977B1 (en) * 1999-09-13 2002-11-26 Cornell Research Foundation, Inc. Recombinant constructs and techniques for delivering to eucaryotic cells bacterial proteins that are secreted via type III secretion systems

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535514A (ja) * 2005-04-11 2008-09-04 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド キメラタンパク質、それらの製造およびそれを含有する医薬組成物
JP2014518061A (ja) * 2011-06-01 2014-07-28 シャモン ユニヴァーシティー ジフテリア毒素の無毒性突然変異体ｃｒｍ１９７又はその断片を含む融合タンパク質

Also Published As

Publication number Publication date
WO2002096467A3 (en) 2003-04-10
JP2009286794A (ja) 2009-12-10
CN100439394C (zh) 2008-12-03
CN1531549A (zh) 2004-09-22
AU2002256803B2 (en) 2006-11-09
US20040208889A1 (en) 2004-10-21
GB0112687D0 (en) 2001-07-18
WO2002096467A2 (en) 2002-12-05
CA2448963A1 (en) 2002-12-05
EP1390400A2 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
JP2009286794A (ja) 分泌された細菌エフェクタータンパク質の薬学的使用
Pei How do biomolecules cross the cell membrane?
Vasconcelos et al. Therapeutic potential of cell-penetrating peptides
US7470661B2 (en) Delivery of superoxide dismutase to neuronal cells
AU2002256803A1 (en) Pharmaceutical use for secreted bacterial effector proteins
US20040071736A1 (en) Methods and compounds for the treatment of mucus hypersecretion
JP2002523377A (ja) 粘液過剰分泌の治療のための組換えボツリヌス菌毒素
WO2018109447A1 (en) Neurotoxins
JP4991073B2 (ja) 神経細胞への治療薬の送達のための構築物
ES2322116B1 (es) Microorganismo productor de anticuerpos, elementos necesarios para su obtencion, anticuerpos asi producidos, composiciones terapeuticas y sus aplicaciones.
CA2406352A1 (en) Peptide conjugates for drug delivery
CN103249401A (zh) 使用细菌毒素衍生的转运序列递送生物活性剂的系统和方法
EP1523336B1 (en) Targeted agents for nerve regeneration
Sahni et al. Bacterial toxins escape the endosome by inducing vesicle budding and collapse
US7368532B2 (en) Constructs for delivery of therapeutic agents to neuronal cells
Lopez et al. A genomic island in Brucella involved in the adhesion to host cells: identification of a new adhesin and a translocation factor
Fahrer et al. Genetically engineered clostridial C2 toxin as a novel delivery system for living mammalian cells
JP6910961B2 (ja) 選択細胞への分子送達に適用する遺伝子操作したボツリヌス菌毒素
Li et al. Expression and characterisation of the heavy chain of tetanus toxin: reconstitution of the fully-recombinant dichain protein in active form
Lorenzetti et al. Genetic grafting of membrane‐acting peptides to the cytotoxin dianthin augments its ability to de‐stabilize lipid bilayers and enhances its cytotoxic potential as the component of transferrin‐toxin conjugates
Jia et al. Highly efficient method for intracellular delivery of proteins mediated by cholera toxin-induced protein internalization
Lin et al. Purification and characterization of a novel cell-penetrating carrier similar to cholera toxin chimeric protein
CA2385172A1 (en) Ab5 toxin b subunit mutants with altered chemical conjugation characteristics
Pinheiro et al. Exploring protein–protein ligation approaches for the cytosolic delivery of antigens using AIP56
Liu et al. Design, preparation and characterization of octopus-like self-releasing intracellular protein transporter LEB5 based on Escherichia coli heat-labile enterotoxin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080303

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080321

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20081009

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090703

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090812

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100302